Search
Vanda Pharmaceuticals Inc
VNDAAdd to Watchlist
5.090USD
+0.050+0.99%
Close 09-11 16:00（ET）
307.11MMarket Cap
LossP/E TTM
Vanda Pharmaceuticals Inc (VNDA) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Vanda Pharmaceuticals Inc in the past month.
Buy
0 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
12.188USD+139.44%
VNDA Analyst Recommendation Trends
In the current month, VNDA has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VNDA average Analyst price target in the last month is 12.188.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
3
3
3
4
4
4
3
3
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
5
5
5
4
4
VNDA Analyst Rating for Peer Comparison
Updated: Sep 13, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, VNDA EPS is projected to reach -0.675 in FY2026Q3, following reported EPS of -1.038 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.32
-0.69
-0.59
-0.68
-0.49
Actual
-2.39
-0.82
-1.04
--
--
Surprise
-80.30%
-18.72%
-76.67%
--
--
FAQs
What is Vanda Pharmaceuticals Inc's expected revenue for the next quarter?
Vanda Pharmaceuticals Inc's expected revenue is 69.30M.
What is Vanda Pharmaceuticals Inc's price target?
Analysts forecast that Vanda Pharmaceuticals Inc's price target is USD 12.19, with the highest forecast at USD 20.00 and the lowest forecast at USD 5.75.
How have Vanda Pharmaceuticals IncVNDA's recent earnings per share performed?
The market expectation was USD -1.04, while Vanda Pharmaceuticals IncVNDA's earnings per share (EPS) for the previous quarter was USD -0.82. EPS for the next quarter is expected at USD -0.68.
What is the analyst rating for Vanda Pharmaceuticals Inc?
Based on the ratings of Vanda Pharmaceuticals Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.